{"id": "article-103_0", "title": "Nebivolol -- Continuing Education Activity", "content": "This\u00a0activity focuses on\u00a0nebivolol, a potent medication used to treat\u00a0hypertension.\u00a0A thorough discussion of\u00a0nebivolol\u2019s dual role as a vasodilator and cardioselective \u03b2-blocker underscores its versatility\u00a0when managing cardiovascular conditions. As a selective \u03b2-blocker targeting \u03b2-1 adrenergic receptors, nebivolol\u2019s mechanism of action\u00a0allows\u00a0modulation of cardiac function while sparing \u03b2-2 receptors in the lungs and smooth muscles. This cardioselective profile\u00a0makes nebivolol crucial\u00a0for managing hypertension and vascular disease. By\u00a0understanding\u00a0its pharmacological actions, indications, contraindications,\u00a0pharmacokinetics, and adverse event profiles, healthcare professionals gain the necessary knowledge to administer this medication effectively.", "contents": "Nebivolol -- Continuing Education Activity. This\u00a0activity focuses on\u00a0nebivolol, a potent medication used to treat\u00a0hypertension.\u00a0A thorough discussion of\u00a0nebivolol\u2019s dual role as a vasodilator and cardioselective \u03b2-blocker underscores its versatility\u00a0when managing cardiovascular conditions. As a selective \u03b2-blocker targeting \u03b2-1 adrenergic receptors, nebivolol\u2019s mechanism of action\u00a0allows\u00a0modulation of cardiac function while sparing \u03b2-2 receptors in the lungs and smooth muscles. This cardioselective profile\u00a0makes nebivolol crucial\u00a0for managing hypertension and vascular disease. By\u00a0understanding\u00a0its pharmacological actions, indications, contraindications,\u00a0pharmacokinetics, and adverse event profiles, healthcare professionals gain the necessary knowledge to administer this medication effectively."}
{"id": "article-103_1", "title": "Nebivolol -- Continuing Education Activity", "content": "Objectives: Identify\u00a0the mechanism of action of nebivolol. Assess\u00a0the adverse\u00a0drug reactions of nebivolol. Determine\u00a0the appropriate clinical monitoring\u00a0of\u00a0patients receiving nebivolol. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from\u00a0nebivolol pharmacotherapy. Access free multiple choice questions on this topic.", "contents": "Nebivolol -- Continuing Education Activity. Objectives: Identify\u00a0the mechanism of action of nebivolol. Assess\u00a0the adverse\u00a0drug reactions of nebivolol. Determine\u00a0the appropriate clinical monitoring\u00a0of\u00a0patients receiving nebivolol. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from\u00a0nebivolol pharmacotherapy. Access free multiple choice questions on this topic."}
{"id": "article-103_2", "title": "Nebivolol -- Indications", "content": "Nebivolol is an FDA-approved medication used to treat hypertension. [1] Beta-blockers are a class of agents used to treat multiple conditions, including\u00a0hypertension, angina, arrhythmias, anxiety, hyperthyroidism, migraine prevention, and prevention of essential tremors. [2] [3] The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines advise against using \u03b2-blockers as the first-line treatment for hypertension and to reserve them for patients\u00a0with comorbidities such as ischemic heart disease. [4]", "contents": "Nebivolol -- Indications. Nebivolol is an FDA-approved medication used to treat hypertension. [1] Beta-blockers are a class of agents used to treat multiple conditions, including\u00a0hypertension, angina, arrhythmias, anxiety, hyperthyroidism, migraine prevention, and prevention of essential tremors. [2] [3] The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines advise against using \u03b2-blockers as the first-line treatment for hypertension and to reserve them for patients\u00a0with comorbidities such as ischemic heart disease. [4]"}
{"id": "article-103_3", "title": "Nebivolol -- Indications", "content": "Beta-blockers fall into\u00a02 categories based on whether they block \u03b2-1 receptors in cardiac muscles, \u03b2-2 receptors in the lungs and smooth muscles, or both. Beta-blockers are also classified as vasodilators\u00a0or non-vasodilators based on their vasodilatory capabilities. The FDA has also approved a fixed-dose combination of nebivolol and valsartan\u00a0for hypertension management. [5]", "contents": "Nebivolol -- Indications. Beta-blockers fall into\u00a02 categories based on whether they block \u03b2-1 receptors in cardiac muscles, \u03b2-2 receptors in the lungs and smooth muscles, or both. Beta-blockers are also classified as vasodilators\u00a0or non-vasodilators based on their vasodilatory capabilities. The FDA has also approved a fixed-dose combination of nebivolol and valsartan\u00a0for hypertension management. [5]"}
{"id": "article-103_4", "title": "Nebivolol -- Indications -- FDA-Approved Indications", "content": "Nebivolol is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. Clinicians should prioritize the use of medications such as \u03b2-blockers, ACE inhibitors, or ARBs for adults with a diagnosis of stable ischemic heart disease (SIHD)\u00a0or hypertension and a history of myocardial infarction or stable angina. Additionally, individuals who have experienced a myocardial infarction or acute coronary syndrome are advised to continue guideline-directed medical therapy (including \u03b2-blockers) for at least 3 years as part of their long-term hypertension management. [4]", "contents": "Nebivolol -- Indications -- FDA-Approved Indications. Nebivolol is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. Clinicians should prioritize the use of medications such as \u03b2-blockers, ACE inhibitors, or ARBs for adults with a diagnosis of stable ischemic heart disease (SIHD)\u00a0or hypertension and a history of myocardial infarction or stable angina. Additionally, individuals who have experienced a myocardial infarction or acute coronary syndrome are advised to continue guideline-directed medical therapy (including \u03b2-blockers) for at least 3 years as part of their long-term hypertension management. [4]"}
{"id": "article-103_5", "title": "Nebivolol -- Indications -- Off-Label Uses", "content": "The 2021 European Society of Cardiology (ESC) Guidelines for Heart Failure suggest nebivolol as a treatment option in combination with first-line therapies. [6] Nebivolol can also\u00a0help manage\u00a0microvascular angina. [7] There is potential for nebivolol\u00a0in\u00a0managing\u00a0cancer therapy-related cardiac dysfunction (CTRCD), but further research is required. [8] [9] [10]", "contents": "Nebivolol -- Indications -- Off-Label Uses. The 2021 European Society of Cardiology (ESC) Guidelines for Heart Failure suggest nebivolol as a treatment option in combination with first-line therapies. [6] Nebivolol can also\u00a0help manage\u00a0microvascular angina. [7] There is potential for nebivolol\u00a0in\u00a0managing\u00a0cancer therapy-related cardiac dysfunction (CTRCD), but further research is required. [8] [9] [10]"}
{"id": "article-103_6", "title": "Nebivolol -- Mechanism of Action", "content": "Nebivolol is a \u03b2-1 adrenergic receptor antagonist that works\u00a0by blocking beta-1 receptors, making it\u00a0a cardioselective \u03b2-blocker. This drug also acts on the vascular endothelium by stimulating nitric oxide (NO) synthase, which induces NO-mediated vasodilation. Nebivolol stimulates NO synthase production from the endothelium via \u03b2-3 agonism, reducing systemic vascular resistance. Beta-blockers such as labetalol and carvedilol also have vasodilatory effects; however, their mechanism is via the blockade of \u03b1-adrenergic receptors. Patients with diabetes mellitus, erectile dysfunction, and vascular disease may have abnormal endothelial function, and nebivolol is more effective in these populations due to its NO-induced vasodilatory effect. [11] [12] [13]", "contents": "Nebivolol -- Mechanism of Action. Nebivolol is a \u03b2-1 adrenergic receptor antagonist that works\u00a0by blocking beta-1 receptors, making it\u00a0a cardioselective \u03b2-blocker. This drug also acts on the vascular endothelium by stimulating nitric oxide (NO) synthase, which induces NO-mediated vasodilation. Nebivolol stimulates NO synthase production from the endothelium via \u03b2-3 agonism, reducing systemic vascular resistance. Beta-blockers such as labetalol and carvedilol also have vasodilatory effects; however, their mechanism is via the blockade of \u03b1-adrenergic receptors. Patients with diabetes mellitus, erectile dysfunction, and vascular disease may have abnormal endothelial function, and nebivolol is more effective in these populations due to its NO-induced vasodilatory effect. [11] [12] [13]"}
{"id": "article-103_7", "title": "Nebivolol -- Mechanism of Action", "content": "Nebivolol is chemically composed of a racemic mixture of L-nebivolol and D-nebivolol. This medication is classified as\u00a0a third-generation \u03b2-1 adrenergic receptor antagonist and has the\u00a0strongest \u03b2-receptor affinity\u00a0of all \u03b2-blockers. This affinity explains its\u00a0excellent tolerability in patients with lung disease. Nebivolol is also unique\u00a0because of its \u03b2-1 vs. \u03b2-1 and \u03b2-2 selectivity. At low doses (\u226410 mg) and in patients who are fast metabolizers, nebivolol is \u03b2-1 selective. However, nebivolol loses its selectivity and blocks \u03b2-1 and \u03b2-2 receptors at higher doses and in patients\u00a0who are\u00a0slower\u00a0metabolizers. [14]", "contents": "Nebivolol -- Mechanism of Action. Nebivolol is chemically composed of a racemic mixture of L-nebivolol and D-nebivolol. This medication is classified as\u00a0a third-generation \u03b2-1 adrenergic receptor antagonist and has the\u00a0strongest \u03b2-receptor affinity\u00a0of all \u03b2-blockers. This affinity explains its\u00a0excellent tolerability in patients with lung disease. Nebivolol is also unique\u00a0because of its \u03b2-1 vs. \u03b2-1 and \u03b2-2 selectivity. At low doses (\u226410 mg) and in patients who are fast metabolizers, nebivolol is \u03b2-1 selective. However, nebivolol loses its selectivity and blocks \u03b2-1 and \u03b2-2 receptors at higher doses and in patients\u00a0who are\u00a0slower\u00a0metabolizers. [14]"}
{"id": "article-103_8", "title": "Nebivolol -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Nebivolol reaches peak plasma concentration after 1.5\u00a0to 4 hours. Since food does not modify its pharmacokinetics, nebivolol tablets may be administered without regard to meals. Distribution: Nebivolol is 98 % protein-bound and binds primarily to albumin.", "contents": "Nebivolol -- Mechanism of Action -- Pharmacokinetics. Absorption: Nebivolol reaches peak plasma concentration after 1.5\u00a0to 4 hours. Since food does not modify its pharmacokinetics, nebivolol tablets may be administered without regard to meals. Distribution: Nebivolol is 98 % protein-bound and binds primarily to albumin."}
{"id": "article-103_9", "title": "Nebivolol -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Nebivolol is primarily metabolized in the liver via direct glucuronidation and secondarily through CYP2D6. The hydroxyl and glucuronide metabolites\u00a0are pharmacologically active. Nebivolol is metabolized by CYP2D6. Pharmacogenetic variations of this enzyme can affect various pharmacokinetics parameters; the active isomer (D-nebivolol) has a half-life of about 12 hours in\u00a0fast metabolizers of CYP2D6 and 19 hours in\u00a0slow metabolizers of CYP2D6. However,\u00a0these variations\u00a0are only mildly\u00a0relevant as the circulating hydroxyl and glucuronide metabolites also contribute to the \u03b2-blocking activity. The clinical efficacy and safety profiles of nebivolol are similar regardless of\u00a0slow or\u00a0fast metabolism status; no dose adjustment is necessary.", "contents": "Nebivolol -- Mechanism of Action -- Pharmacokinetics. Metabolism: Nebivolol is primarily metabolized in the liver via direct glucuronidation and secondarily through CYP2D6. The hydroxyl and glucuronide metabolites\u00a0are pharmacologically active. Nebivolol is metabolized by CYP2D6. Pharmacogenetic variations of this enzyme can affect various pharmacokinetics parameters; the active isomer (D-nebivolol) has a half-life of about 12 hours in\u00a0fast metabolizers of CYP2D6 and 19 hours in\u00a0slow metabolizers of CYP2D6. However,\u00a0these variations\u00a0are only mildly\u00a0relevant as the circulating hydroxyl and glucuronide metabolites also contribute to the \u03b2-blocking activity. The clinical efficacy and safety profiles of nebivolol are similar regardless of\u00a0slow or\u00a0fast metabolism status; no dose adjustment is necessary."}
{"id": "article-103_10", "title": "Nebivolol -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: Nebivolol is excreted via\u00a0urine (35%) and\u00a0feces (44%); patients who are\u00a0slow metabolizers excrete 67% in urine and 13% in feces. Nebivolol\u00a0is excreted as oxidative metabolites or glucuronide conjugates. [15]", "contents": "Nebivolol -- Mechanism of Action -- Pharmacokinetics. Elimination: Nebivolol is excreted via\u00a0urine (35%) and\u00a0feces (44%); patients who are\u00a0slow metabolizers excrete 67% in urine and 13% in feces. Nebivolol\u00a0is excreted as oxidative metabolites or glucuronide conjugates. [15]"}
{"id": "article-103_11", "title": "Nebivolol -- Administration -- Available Dosage Forms and Strengths", "content": "Nebivolol is administered orally and\u00a0is not\u00a0available in intravenous form. Oral tablets are available as\u00a0nebivolol hydrochloride salt equivalent to 2.5, 5, 10, and 20 mg of nebivolol.", "contents": "Nebivolol -- Administration -- Available Dosage Forms and Strengths. Nebivolol is administered orally and\u00a0is not\u00a0available in intravenous form. Oral tablets are available as\u00a0nebivolol hydrochloride salt equivalent to 2.5, 5, 10, and 20 mg of nebivolol."}
{"id": "article-103_12", "title": "Nebivolol -- Administration -- Adult Dosage", "content": "Hypertension: In a patient with hypertension, nebivolol dosing should be based on the patient's individual needs. The recommended starting dose for most patients is 5 mg once daily, which\u00a0can\u00a0be taken independently of meals. If further\u00a0blood pressure reduction is necessary, the dose can be titrated up at 2 to 4-week intervals based on the clinical response. The maximum dose is 40 mg once daily. Nebivolol is a CYP2D6 substrate; drug-drug interactions should be considered before prescribing nebivolol.\u00a0A recent review suggests that nebivolol\u00a0is also effective in African-American patients with hypertension, who demonstrate\u00a0decreased\u00a0responsiveness to \u03b2-blockers\u00a0compared to other ethnicities. [16]", "contents": "Nebivolol -- Administration -- Adult Dosage. Hypertension: In a patient with hypertension, nebivolol dosing should be based on the patient's individual needs. The recommended starting dose for most patients is 5 mg once daily, which\u00a0can\u00a0be taken independently of meals. If further\u00a0blood pressure reduction is necessary, the dose can be titrated up at 2 to 4-week intervals based on the clinical response. The maximum dose is 40 mg once daily. Nebivolol is a CYP2D6 substrate; drug-drug interactions should be considered before prescribing nebivolol.\u00a0A recent review suggests that nebivolol\u00a0is also effective in African-American patients with hypertension, who demonstrate\u00a0decreased\u00a0responsiveness to \u03b2-blockers\u00a0compared to other ethnicities. [16]"}
{"id": "article-103_13", "title": "Nebivolol -- Administration -- Adult Dosage", "content": "Nebivolol\u00a0should never be\u00a0discontinued abruptly, and taper-off dosing\u00a0is recommended if the patient needs to stop using nebivolol. Rebound hypertension, tachycardia, exacerbation of cardiac arrhythmia, and hospitalization are reported when \u03b2-blockers are stopped abruptly. [17]", "contents": "Nebivolol -- Administration -- Adult Dosage. Nebivolol\u00a0should never be\u00a0discontinued abruptly, and taper-off dosing\u00a0is recommended if the patient needs to stop using nebivolol. Rebound hypertension, tachycardia, exacerbation of cardiac arrhythmia, and hospitalization are reported when \u03b2-blockers are stopped abruptly. [17]"}
{"id": "article-103_14", "title": "Nebivolol -- Administration -- Specific Patient Population", "content": "Hepatic impairment: Per product labeling, the initial recommended dose is 2.5 mg orally once daily, which is titrated slowly (if needed) for patients with moderate hepatic impairment. No data is available on nebivolol use\u00a0for patients with severe hepatic impairment.", "contents": "Nebivolol -- Administration -- Specific Patient Population. Hepatic impairment: Per product labeling, the initial recommended dose is 2.5 mg orally once daily, which is titrated slowly (if needed) for patients with moderate hepatic impairment. No data is available on nebivolol use\u00a0for patients with severe hepatic impairment."}
{"id": "article-103_15", "title": "Nebivolol -- Administration -- Specific Patient Population", "content": "Renal impairment: Per product labeling, the initial recommended dose for patients with severe renal impairment (CrCl <30 mL/min) is 2.5 mg orally once daily, titrated slowly if needed. There is no data available on nebivolol use\u00a0for patients on dialysis.", "contents": "Nebivolol -- Administration -- Specific Patient Population. Renal impairment: Per product labeling, the initial recommended dose for patients with severe renal impairment (CrCl <30 mL/min) is 2.5 mg orally once daily, titrated slowly if needed. There is no data available on nebivolol use\u00a0for patients on dialysis."}
{"id": "article-103_16", "title": "Nebivolol -- Administration -- Specific Patient Population", "content": "Pregnancy considerations: Nebivolol\u00a0is a former\u00a0FDA pregnancy Category C\u00a0medicine.\u00a0If nebivolol is required\u00a0for a pregnant woman with a history of hypertension, then fetal monitoring is indicated.\u00a0The baby should be monitored for the first 48 hours post-delivery for possible\u00a0hypoglycemia, bradycardia, and respiratory depression. [18] [19] The American College of Gynecology & Obstetrics (ACOG) recommends treatment with labetalol for hypertensive disorders of pregnancy. [20]", "contents": "Nebivolol -- Administration -- Specific Patient Population. Pregnancy considerations: Nebivolol\u00a0is a former\u00a0FDA pregnancy Category C\u00a0medicine.\u00a0If nebivolol is required\u00a0for a pregnant woman with a history of hypertension, then fetal monitoring is indicated.\u00a0The baby should be monitored for the first 48 hours post-delivery for possible\u00a0hypoglycemia, bradycardia, and respiratory depression. [18] [19] The American College of Gynecology & Obstetrics (ACOG) recommends treatment with labetalol for hypertensive disorders of pregnancy. [20]"}
{"id": "article-103_17", "title": "Nebivolol -- Administration -- Specific Patient Population", "content": "Breastfeeding considerations: There is no information on using nebivolol\u00a0for\u00a0women who are breastfeeding. The risk of \u03b2-blockers causing bradycardia in breastfed infants should be considered, and an alternate drug with safer profiles should be administered. [19] Pediatric patients: The safety and efficacy of nebivolol\u00a0for pediatric patients have not been verified.", "contents": "Nebivolol -- Administration -- Specific Patient Population. Breastfeeding considerations: There is no information on using nebivolol\u00a0for\u00a0women who are breastfeeding. The risk of \u03b2-blockers causing bradycardia in breastfed infants should be considered, and an alternate drug with safer profiles should be administered. [19] Pediatric patients: The safety and efficacy of nebivolol\u00a0for pediatric patients have not been verified."}
{"id": "article-103_18", "title": "Nebivolol -- Administration -- Specific Patient Population", "content": "Older patients: The SENIORS study assessed nebivolol's effects in heart failure patients aged 70 or older, regardless of ejection fraction. Nebivolol reduced combined mortality and cardiovascular admissions compared to placebo, independent of age, gender, or ejection fraction. In conclusion, nebivolol was effective and well-tolerated in older\u00a0patients with heart failure. [21]", "contents": "Nebivolol -- Administration -- Specific Patient Population. Older patients: The SENIORS study assessed nebivolol's effects in heart failure patients aged 70 or older, regardless of ejection fraction. Nebivolol reduced combined mortality and cardiovascular admissions compared to placebo, independent of age, gender, or ejection fraction. In conclusion, nebivolol was effective and well-tolerated in older\u00a0patients with heart failure. [21]"}
{"id": "article-103_19", "title": "Nebivolol -- Adverse Effects", "content": "Nebivolol's reported adverse effects typically involve the central nervous system (CNS). Headache is the most commonly reported\u00a0adverse\u00a0effect (6% to 9%). [22] [23] Other common\u00a0adverse effects include: [24] Fatigue (Dose-dependent) Dizziness Rhinitis Insomnia Asthenia Hyperuricemia Paresthesias Weakness Some less observed adverse\u00a0drug reactions are skin rash\u00a0and\u00a0gastrointestinal\u00a0adverse effects such as diarrhea, nausea, and abdominal pain. Less common\u00a0adverse effects\u00a0documented in case reports and post-marketing reports include: Acute pulmonary edema Acute kidney injury Second and third-degree atrioventricular (AV) block Bronchospasm Angioedema Hypersensitivity reaction Claudication Drug-induced liver injury:\u00a0elevated serum ALT, AST, and serum bilirubin Thrombocytopenia Raynaud phenomenon Somnolence Syncope Erectile dysfunction (less common than for conventional \u03b2-blockers) [16] [25] Psoriasis [26]", "contents": "Nebivolol -- Adverse Effects. Nebivolol's reported adverse effects typically involve the central nervous system (CNS). Headache is the most commonly reported\u00a0adverse\u00a0effect (6% to 9%). [22] [23] Other common\u00a0adverse effects include: [24] Fatigue (Dose-dependent) Dizziness Rhinitis Insomnia Asthenia Hyperuricemia Paresthesias Weakness Some less observed adverse\u00a0drug reactions are skin rash\u00a0and\u00a0gastrointestinal\u00a0adverse effects such as diarrhea, nausea, and abdominal pain. Less common\u00a0adverse effects\u00a0documented in case reports and post-marketing reports include: Acute pulmonary edema Acute kidney injury Second and third-degree atrioventricular (AV) block Bronchospasm Angioedema Hypersensitivity reaction Claudication Drug-induced liver injury:\u00a0elevated serum ALT, AST, and serum bilirubin Thrombocytopenia Raynaud phenomenon Somnolence Syncope Erectile dysfunction (less common than for conventional \u03b2-blockers) [16] [25] Psoriasis [26]"}
{"id": "article-103_20", "title": "Nebivolol -- Adverse Effects -- Drug-Drug Interactions", "content": "The CYP2D6 system metabolizes nebivolol. The dose may need to be reduced when giving nebivolol and CYP2D6 inhibitors. Nebivolol's potential drug-drug interactions include medication classes that are either substrate or inhibitors/inducers of CYP2D6. [16]", "contents": "Nebivolol -- Adverse Effects -- Drug-Drug Interactions. The CYP2D6 system metabolizes nebivolol. The dose may need to be reduced when giving nebivolol and CYP2D6 inhibitors. Nebivolol's potential drug-drug interactions include medication classes that are either substrate or inhibitors/inducers of CYP2D6. [16]"}
{"id": "article-103_21", "title": "Nebivolol -- Adverse Effects -- Drug-Drug Interactions", "content": "CYP2D6 substrates: antiarrhythmics (class 1), 5-HT3 receptor antagonists, antidepressants, analgesics (opioids), protease inhibitors (ritonavir),\u00a0antipsychotics, cholinesterase inhibitors CYP2D6 inhibitors: antiarrhythmics (class 3), antihistamines, antipsychotics, protease inhibitors (eg, ritonavir, tipranavir), antimalarials, H2 receptor antagonists CYP2D6 inducers: antiseizure medications When \u03b2-blockers are administered with non-dihydropyridine calcium channel blockers (eg, verapamil, diltiazem), they may cause significant negative inotropic and chronotropic effects. EKG and blood pressure monitoring are recommended when\u00a0these agents are administered together. [27] Rivastigmine administered with \u03b2-blockers can\u00a0cause bradycardia and possible syncope. [3]", "contents": "Nebivolol -- Adverse Effects -- Drug-Drug Interactions. CYP2D6 substrates: antiarrhythmics (class 1), 5-HT3 receptor antagonists, antidepressants, analgesics (opioids), protease inhibitors (ritonavir),\u00a0antipsychotics, cholinesterase inhibitors CYP2D6 inhibitors: antiarrhythmics (class 3), antihistamines, antipsychotics, protease inhibitors (eg, ritonavir, tipranavir), antimalarials, H2 receptor antagonists CYP2D6 inducers: antiseizure medications When \u03b2-blockers are administered with non-dihydropyridine calcium channel blockers (eg, verapamil, diltiazem), they may cause significant negative inotropic and chronotropic effects. EKG and blood pressure monitoring are recommended when\u00a0these agents are administered together. [27] Rivastigmine administered with \u03b2-blockers can\u00a0cause bradycardia and possible syncope. [3]"}
{"id": "article-103_22", "title": "Nebivolol -- Contraindications", "content": "Nebivolol should be used cautiously with a history of severe anaphylaxis to various allergens. Repeat challenges among patients taking \u03b2-blockers may cause increased sensitivity to severe anaphylaxis. Treating anaphylaxis in patients\u00a0using \u03b2-blockers may not be effective and promote undesirable effects. [28] [29] [30]", "contents": "Nebivolol -- Contraindications. Nebivolol should be used cautiously with a history of severe anaphylaxis to various allergens. Repeat challenges among patients taking \u03b2-blockers may cause increased sensitivity to severe anaphylaxis. Treating anaphylaxis in patients\u00a0using \u03b2-blockers may not be effective and promote undesirable effects. [28] [29] [30]"}
{"id": "article-103_23", "title": "Nebivolol -- Contraindications", "content": "Nebivolol is contraindicated in severe bradycardia, cardiogenic shock, decompensated heart failure, second or\u00a0third-degree heart block,\u00a0severe hepatic impairment, and sick sinus syndrome. However, it is still useful if a functioning pacemaker is present. [31]", "contents": "Nebivolol -- Contraindications. Nebivolol is contraindicated in severe bradycardia, cardiogenic shock, decompensated heart failure, second or\u00a0third-degree heart block,\u00a0severe hepatic impairment, and sick sinus syndrome. However, it is still useful if a functioning pacemaker is present. [31]"}
{"id": "article-103_24", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Other disease-related/age group-related relative contraindications include:", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Other disease-related/age group-related relative contraindications include:"}
{"id": "article-103_25", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Bronchospastic disease: \u03b2-blockers are not recommended in patients with bronchospastic disease.", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Bronchospastic disease: \u03b2-blockers are not recommended in patients with bronchospastic disease."}
{"id": "article-103_26", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Diabetes: Nebivolol may enhance hypoglycemia and mask signs and symptoms (eg, tachycardia) of hypoglycemia.", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Diabetes: Nebivolol may enhance hypoglycemia and mask signs and symptoms (eg, tachycardia) of hypoglycemia."}
{"id": "article-103_27", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Hepatic impairment:\u00a0Nebivolol\u00a0is contraindicated in patients with Child-Pugh Class C hepatic impairment.", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Hepatic impairment:\u00a0Nebivolol\u00a0is contraindicated in patients with Child-Pugh Class C hepatic impairment."}
{"id": "article-103_28", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Myasthenia gravis: Nebivolol should be used cautiously in patients with myasthenia gravis.", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Myasthenia gravis: Nebivolol should be used cautiously in patients with myasthenia gravis."}
{"id": "article-103_29", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Peripheral vascular disease (PVD) and Raynaud disease: Nebivolol can precipitate the symptoms of arterial insufficiency.", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Peripheral vascular disease (PVD) and Raynaud disease: Nebivolol can precipitate the symptoms of arterial insufficiency."}
{"id": "article-103_30", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Pheochromocytoma (not on treatment): The patient should be\u00a0administered \u03b1-blockers before any \u03b2-blockers.", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Pheochromocytoma (not on treatment): The patient should be\u00a0administered \u03b1-blockers before any \u03b2-blockers."}
{"id": "article-103_31", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Psoriasis: \u03b2-blockers can induce or exacerbate psoriasis, but the cause and effect remain unestablished. The proposed mechanism indicates that \u03b2-blockers cause intracellular changes in calcium,\u00a0affecting\u00a0keratinocyte and granulocyte function\u00a0by reducing cyclic adenosine monophosphate (cAMP) levels. [26]", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Psoriasis: \u03b2-blockers can induce or exacerbate psoriasis, but the cause and effect remain unestablished. The proposed mechanism indicates that \u03b2-blockers cause intracellular changes in calcium,\u00a0affecting\u00a0keratinocyte and granulocyte function\u00a0by reducing cyclic adenosine monophosphate (cAMP) levels. [26]"}
{"id": "article-103_32", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Renal impairment: Dose adjustment is necessary with severe renal impairment (CrCl <30 mL/min).", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Renal impairment: Dose adjustment is necessary with severe renal impairment (CrCl <30 mL/min)."}
{"id": "article-103_33", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Thyroid disease: Nebivolol may mask signs and symptoms of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, careful management and monitoring are required. Abrupt withdrawal may worsen symptoms of hyperthyroidism or precipitate thyroid storm.", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Thyroid disease: Nebivolol may mask signs and symptoms of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, careful management and monitoring are required. Abrupt withdrawal may worsen symptoms of hyperthyroidism or precipitate thyroid storm."}
{"id": "article-103_34", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Pregnancy: Category C medication; it is unclear if nebivolol gets excreted in breast milk; \u03b2-blockers can cause serious adverse\u00a0effects in nursing infants (eg, bradycardia).", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Pregnancy: Category C medication; it is unclear if nebivolol gets excreted in breast milk; \u03b2-blockers can cause serious adverse\u00a0effects in nursing infants (eg, bradycardia)."}
{"id": "article-103_35", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Older\u00a0population: Increased frequency of bradycardia in patients aged 65 or older; dose reduction should be considered.", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Older\u00a0population: Increased frequency of bradycardia in patients aged 65 or older; dose reduction should be considered."}
{"id": "article-103_36", "title": "Nebivolol -- Contraindications -- Warning and Precautions", "content": "Surgery: Per ACC/AHA guidelines, patients with hypertension and a history of chronic\u00a0\u03b2-blocker use who are preparing for major surgery should continue their \u03b2-blocker regimen. However, initiating \u03b2-blockers the day of surgery is not recommended for patients who have not previously used them. [4]", "contents": "Nebivolol -- Contraindications -- Warning and Precautions. Surgery: Per ACC/AHA guidelines, patients with hypertension and a history of chronic\u00a0\u03b2-blocker use who are preparing for major surgery should continue their \u03b2-blocker regimen. However, initiating \u03b2-blockers the day of surgery is not recommended for patients who have not previously used them. [4]"}
{"id": "article-103_37", "title": "Nebivolol -- Monitoring", "content": "Parameters that should be monitored include: Blood pressure EKG for possible bradycardia Serum glucose in patients with diabetes mellitus [31]", "contents": "Nebivolol -- Monitoring. Parameters that should be monitored include: Blood pressure EKG for possible bradycardia Serum glucose in patients with diabetes mellitus [31]"}
{"id": "article-103_38", "title": "Nebivolol -- Toxicity -- Signs and Symptoms of Overdose", "content": "Clinical presentations of nebivolol overdose usually include bradycardia\u00a0and hypotension. Further adverse effects linked to excessive nebivolol intake can cause\u00a0vomiting,\u00a0heart failure, bronchospasm, and\u00a0AV\u00a0block.", "contents": "Nebivolol -- Toxicity -- Signs and Symptoms of Overdose. Clinical presentations of nebivolol overdose usually include bradycardia\u00a0and hypotension. Further adverse effects linked to excessive nebivolol intake can cause\u00a0vomiting,\u00a0heart failure, bronchospasm, and\u00a0AV\u00a0block."}
{"id": "article-103_39", "title": "Nebivolol -- Toxicity -- Management of Overdose", "content": "Glucagon is the first-line treatment for \u03b2-blocker overdose. Glucagon is only effective for a short time, and prolonged use can cause tachyphylaxis,\u00a0rendering\u00a0therapy ineffective. Glucagon is administered intravenously (IV) as a slow bolus followed by a continuous infusion. The initial bolus dose is typically 5 mg administered over\u00a01 minute. Constant\u00a0heart rate and blood pressure monitoring are required. If\u00a0these measures do not increase after 15 minutes, administer another bolus. Glucagon starts working within 3 minutes, with a peak response at 5\u00a0to 7 minutes. If there is no notable effect within 10 minutes\u00a0of the\u00a0second bolus, then it is doubtful that an infusion would benefit the patient. If there is an increase in heart rate and blood pressure, an infusion will be beneficial. The infusion rate should be\u00a0between 2 to 5 mg/h. The goal is a mean arterial pressure (MAP) of 60 mm Hg. If a MAP of 60 mm Hg cannot be achieved, the patient\u00a0may require additional therapies. [32] [33]", "contents": "Nebivolol -- Toxicity -- Management of Overdose. Glucagon is the first-line treatment for \u03b2-blocker overdose. Glucagon is only effective for a short time, and prolonged use can cause tachyphylaxis,\u00a0rendering\u00a0therapy ineffective. Glucagon is administered intravenously (IV) as a slow bolus followed by a continuous infusion. The initial bolus dose is typically 5 mg administered over\u00a01 minute. Constant\u00a0heart rate and blood pressure monitoring are required. If\u00a0these measures do not increase after 15 minutes, administer another bolus. Glucagon starts working within 3 minutes, with a peak response at 5\u00a0to 7 minutes. If there is no notable effect within 10 minutes\u00a0of the\u00a0second bolus, then it is doubtful that an infusion would benefit the patient. If there is an increase in heart rate and blood pressure, an infusion will be beneficial. The infusion rate should be\u00a0between 2 to 5 mg/h. The goal is a mean arterial pressure (MAP) of 60 mm Hg. If a MAP of 60 mm Hg cannot be achieved, the patient\u00a0may require additional therapies. [32] [33]"}
{"id": "article-103_40", "title": "Nebivolol -- Toxicity -- Management of Overdose", "content": "Supportive care is required in overdose. Intravenous atropine administration\u00a0may be\u00a0required to manage bradycardia. Transthoracic or transvenous pacemaker placement may be necessary for heart block (second or third-degree). Intravenous fluids should be administered for hypotension, while inhaled \u03b2-2 agonists are indicated for bronchospasm. Intravenous glucose is advised for managing hypoglycemia.", "contents": "Nebivolol -- Toxicity -- Management of Overdose. Supportive care is required in overdose. Intravenous atropine administration\u00a0may be\u00a0required to manage bradycardia. Transthoracic or transvenous pacemaker placement may be necessary for heart block (second or third-degree). Intravenous fluids should be administered for hypotension, while inhaled \u03b2-2 agonists are indicated for bronchospasm. Intravenous glucose is advised for managing hypoglycemia."}
{"id": "article-103_41", "title": "Nebivolol -- Toxicity -- Management of Overdose", "content": "Treating anaphylaxis in the setting of \u03b2-blocker administration\u00a0can be challenging. If epinephrine is ineffective, then glucagon\u00a0should be administered as\u00a0it can reverse refractory hypotension and bronchospasm during anaphylaxis in patients on \u03b2-blockers. Glucagon works by activating adenyl cyclase directly. [34]", "contents": "Nebivolol -- Toxicity -- Management of Overdose. Treating anaphylaxis in the setting of \u03b2-blocker administration\u00a0can be challenging. If epinephrine is ineffective, then glucagon\u00a0should be administered as\u00a0it can reverse refractory hypotension and bronchospasm during anaphylaxis in patients on \u03b2-blockers. Glucagon works by activating adenyl cyclase directly. [34]"}
{"id": "article-103_42", "title": "Nebivolol -- Enhancing Healthcare Team Outcomes", "content": "Nebivolol is a\u00a0medication that is FDA-approved to treat hypertension. All interprofessional healthcare team members must be aware of the\u00a0current indications, interactions, adverse effects, and other pharmacodynamics and pharmacokinetic factors that can affect successful therapy implementation and improve patient outcomes. [12] [35] Cardiologists treat refractory hypertension and complications associated with therapy. Pharmacists review the appropriateness of the selected drug and the dose, look for interactions or other contraindications, and consult the prescriber as necessary. They also counsel patients and their families about appropriate use and\u00a0adverse effects. Nurses monitor vital signs, counsel the patient on dosing and administration, monitor for potential adverse effects, and report issues to the team for therapy adjustment. In an overdose of nebivolol, critical care\u00a0input is crucial. A medical toxicologist should be consulted as the direct care provided by these specialists has been shown to reduce the length of stay and decrease healthcare utilization. [36]", "contents": "Nebivolol -- Enhancing Healthcare Team Outcomes. Nebivolol is a\u00a0medication that is FDA-approved to treat hypertension. All interprofessional healthcare team members must be aware of the\u00a0current indications, interactions, adverse effects, and other pharmacodynamics and pharmacokinetic factors that can affect successful therapy implementation and improve patient outcomes. [12] [35] Cardiologists treat refractory hypertension and complications associated with therapy. Pharmacists review the appropriateness of the selected drug and the dose, look for interactions or other contraindications, and consult the prescriber as necessary. They also counsel patients and their families about appropriate use and\u00a0adverse effects. Nurses monitor vital signs, counsel the patient on dosing and administration, monitor for potential adverse effects, and report issues to the team for therapy adjustment. In an overdose of nebivolol, critical care\u00a0input is crucial. A medical toxicologist should be consulted as the direct care provided by these specialists has been shown to reduce the length of stay and decrease healthcare utilization. [36]"}
{"id": "article-103_43", "title": "Nebivolol -- Enhancing Healthcare Team Outcomes", "content": "If an overdose is intentional, a psychiatric consultation should be obtained. Nebivolol therapy has its best chance for therapeutic success with minimal adverse events if the interprofessional teamwork\u00a0between MDs, DOs, PAs, NPs, and pharmacists is in place.\u00a0The 2017 ACC/AHA guidelines for hypertension recommend interprofessional team-based care,\u00a0which involves\u00a0primary care providers, patients, cardiologists,\u00a0physician assistants, nurses, pharmacists, dietitians, community health workers, and social workers.\u00a0Randomized controlled trials\u00a0and meta-analyses of interprofessional team-based hypertension care involving nurse or pharmacist-led lead intervention have demonstrated optimal blood pressure control compared\u00a0to routine care. [37] [38] [39]", "contents": "Nebivolol -- Enhancing Healthcare Team Outcomes. If an overdose is intentional, a psychiatric consultation should be obtained. Nebivolol therapy has its best chance for therapeutic success with minimal adverse events if the interprofessional teamwork\u00a0between MDs, DOs, PAs, NPs, and pharmacists is in place.\u00a0The 2017 ACC/AHA guidelines for hypertension recommend interprofessional team-based care,\u00a0which involves\u00a0primary care providers, patients, cardiologists,\u00a0physician assistants, nurses, pharmacists, dietitians, community health workers, and social workers.\u00a0Randomized controlled trials\u00a0and meta-analyses of interprofessional team-based hypertension care involving nurse or pharmacist-led lead intervention have demonstrated optimal blood pressure control compared\u00a0to routine care. [37] [38] [39]"}
{"id": "article-103_44", "title": "Nebivolol -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Nebivolol -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}